Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
3. Worldwide WT Classification Systems
4. The Prognostic Value of Patient Characteristics
4.1. Age
4.2. Sex and Race
5. The Prognostic Significance of Tumor Stage
5.1. Stage I and II
Authors | Ref. | Study | n | Tumor Characteristics and Stratifiers | Survival Rates | p-Value 1 |
---|---|---|---|---|---|---|
D.M. Green et al. 1998 | [38] | NWTS-4 | 1543 | Stage I–IV, FH Pulse-intensive (single-dose)/standard (divided-dose) chemotherapy regimen | 2-year RFS: pulse-intensive/standard regimen Stage I: 94.9/92.5% Stage II: 85.9/89.7% Stage III: 91.1/95.3% Stage IV: 80.6/81.3% | NA |
E.J. Gratias et al. 2016 | [29] | NWTS-5 | 1114 | Stage I–IV, FH 1q gain/no 1q gain | 8-year EFS: 1q gain/no 1q gain Stage I: 85% (72–98%)/95% (91–99%) Stage II: 81% (71–91%)/87% (83–92%) Stage III: 79% (70–87%)/89% (84–94%) Stage IV: 64% (48–79%)/91% (83–99%) | NA |
D. B. Dix et al. 2019 | [42] | NWTS-5 AREN0532 AREN0533 | 168 | Stage I–IV, FH, with LOH 1p/16q Study protocol: NWTS-5/AREN | 4-year EFS: NWTS-5/AREN study protocols Stage I–II: 68.8% (55.2–82.3%)/87.3% (75.1–99.5%) Stage III–IV: 61.3% (44.9–77.6%)/90.2% (81.7–98.6%) | NA |
N.C. Daw et al. 2020 | [43] | AREN0321 | 66 | Stage II–IV, DA | 4-year EFS: Stage II: 86% (68.8–100%) Stage III: 80.9% (65.8–96%) Stage IV: 41.7% (19.6–63.7%) | NA |
J.S. Dome et al. 2006 | [44] | NWTS-5 | 124 | Stage I–IV, AH | 4-year EFS Stage I: 69.5% (46.9–84.0) Stage II: 82.1% (62.3–92.1%) Stage III: 68.3% (53.6–79.3%) Stage IV: 37.5% (15.4–59.8%) | NA |
D.M. Green et al. 1994 | [45] | NWTS-3 NWTS-4 | 59 | Stage II–IV, DA Treatment without Cy/with Cy | 4-year RFS: without Cy/with Cy Stage II: 40.0%/71.6% Stage III: 33.3%/58.7% Stage IV: 0.0%/16.7% | NA |
Authors | Ref. | Cooperative Group | Study | n | Outcome | Comparison | Hazard Ratio | p-Value |
---|---|---|---|---|---|---|---|---|
T. Koshinaga et al. 2018 | [4] | JWiTS | JWiTS-2 | 178 | EFS | I–III vs. IV 1 | Significant (Log-rank) | <0.01 |
F. Spreafico et al. 2017 | [5] | AIEOP | TW2003 | 453 | EFS | I vs. II | 1.13 (0.56–2.29) | n.s. |
I vs. III | 0.96 (0.40–2.30) | |||||||
I vs. IV | 1.90 (0.82–4.42) | |||||||
S. Irtan et al. 2015 | [25] | UKCCLG | UKW3 | 635 | Local RFS | I vs. II I vs. III I vs. IV | n.s. in UVA | n.s. |
Distant RFS | I vs. II I vs. III I vs. IV | 0.99 (0.46–2.12) 1.46 (0.80–2.27) 2.35 (1.27–4.33) In UVA | n.s. in MVA | |||||
M. Haruta et al. 2019 | [33] | JWiTS | 1987–2015 | 128 | EFS | I–III vs. IV 1 | 0.86 (0.79–0.93) vs. 0.54 (0.25–0.82) | 0.006 |
B. Messahel et al. 2009 | [46] | UKCCLG | UKW1-3 | 452 | RFS | I–II vs. III–IV 2 | 1.35 (0.78–2.31) | 0.28 |
H. Segers et al. 2013 | [47] | SIOP/UKCCLG | SIOP2001, UKW2-3 3 | 272 | EFS | I vs. II | 1.23 (0.49–3.12) | 0.66 |
I vs. III | 2.29 (1.01–5.21) | 0.05 | ||||||
I vs. IV | 3.63 (1.62–8.13) | 0.002 |
Authors | Ref. | Study | n | Outcome | Comparison | Hazard Ratio | p-Value |
---|---|---|---|---|---|---|---|
J.A. et al. Hol 2019 | [22] | SIOP9301, SIOP2001 | 4596 | I vs. II | EFS | 1.13 (0.91–1.41) | 0.28 |
I vs. III | 1.60 (1.28–2.00) | <0.0001 | |||||
I vs. IV | 2.97 (2.40–3.67) | <0.0001 | |||||
S. Irtan et al. 2019 | [23] | SIOP2001 | 2971 | I vs. II Abdominal stage | Local RFS | n.s. | n.s. |
Distant RFS | 1.58 (1.15–2.17) | 0.005 | |||||
I vs. III Abdominal stage | Local RFS | n.s. | n.s. | ||||
Distant RFS | 1.52 (1.00–2.32) | 0.05 | |||||
I–III vs. IV | Local RFS | n.s. | n.s. | ||||
Distant RFS | 2.50 (1.88–3.31) | <0.0001 | |||||
A. Weirich et al. 2004 | [24] | SIOP-9/GPOH | 440 | I–II vs. III | RFS | n.s. | n.s. |
I–III vs. IV–V 1 | 2.7 | 0.0003 | |||||
T. Chagtai et al. 2016 | [27] | SIOP2001 | 585 | I vs. II | EFS | 1.27 (0.71–2.27) | 0.43 |
I vs. III | 1.52 (0.83–2.79) | 0.17 |
5.2. Stage III
5.2.1. Lymph Node Status
5.2.2. Tumor Spill
5.2.3. Tumor Biopsy
5.2.4. Residual Disease
5.2.5. Summary
5.3. Stage IV
5.4. Bilateral Disease (Stage V)
6. The Prognostic Significance of Tumor Histology
6.1. Anaplasia
6.2. Blastemal-Type WT
6.3. SIOP Non-Anaplastic and Non-Blastemal Histological WT Subtypes
6.4. Tumor Volume
7. The Prognostic Significance of Genetic Aberrations
7.1. Germline Mutations
7.2. Somatic Mutations
7.3. Coopy Number Variations
7.3.1. Gain of 1q
7.3.2. LOH of 1p and 16q
8. Is Prognosis Influenced by Administered Treatment?
8.1. Pre-Operative Chemotherapy Versus Immediate Nephrectomy
8.2. Chemotherapy: Doxorubicin
8.3. Radiotherapy
8.4. Surgery
NSS and MIS
8.5. Refractory Disease during First-Line Treatment
8.6. Centralization of Expertise
9. The Prognostic Significance of Geographic and Socioeconomic Factors
10. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
Abbreviations
AH | Anaplastic histology |
AHWT | Anaplastic histology Wilms tumor |
AIEOP | Associazione Italiana Ematologia Oncologia Pediatrica |
COG-RTC | Children’s Oncology Group Renal Tumor Committee |
CT | Computed tomography |
Cy | Cyclophosphamide |
DA | Diffuse anaplasia |
Dox | Doxorubicin |
EFS | Event-free survival |
ERN PaedCan | European Reference Network–Paediatric Cancer |
ExPO-r-Net | European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment |
FA | Focal anaplasia |
FHWT | Favorable histology Wilms tumor |
GFAOP | French African Pediatric Oncology Group |
GPOH | Gesellschaft für pädiatrische Onkologie und Hämatologie |
HR | High risk |
IMRT | Intensity Modulated RadioTherapy |
IR | Intermediate risk |
JWiTS | Japan Wilms Tumor Study |
LOH | Loss of heterozygosity |
LOI | Loss of imprinting |
LR | Low risk |
miRNAPGs | microRNA processing genes |
MIS | Minimally invasive surgery |
MVA | Multivariable analysis |
N | Number of patients |
NA | Not applicable |
n.s. | Not significant |
NSS | Nephron-sparing surgery |
NWTSG | National Wilms Tumor Study Group |
OS | Overall survival |
PODC | Pediatric Oncology in Developing Countries |
Ref | Reference |
RFS | Recurrence-free survival |
SIOP-RTSG | International Society of Pediatric Oncology Renal Tumor Study Group |
UKCCLG | United Kingdom Children’s Cancer and Leukaemia Group |
UVA | Univariable analysis |
VA | Vincristin, Actinomycin-D |
VAD | Vincristin, Actinomycin-D and Doxorubicin |
VLRWT | Very low risk Wilms tumor |
WAGR | Wilms tumor, aniridia, genitourinary anomalies, and range of developmental delays |
WT | Wilms tumor |
Appendix A. Search Strategy
References
- Dome, J.S.; Graf, N.; Geller, J.I.; Fernandez, C.V.; Mullen, E.A.; Spreafico, F.; Van den Heuvel-Eibrink, M.; Pritchard-Jones, K. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. J. Clin. Oncol. 2015, 33, 2999–3007. [Google Scholar] [CrossRef] [PubMed]
- Van den Heuvel-Eibrink, M.M.; Hol, J.A.; Pritchard-Jones, K.; van Tinteren, H.; Furtwangler, R.; Verschuur, A.C.; Vujanic, G.M.; Leuschner, I.; Brok, J.; Rube, C.; et al. Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol. Nat. Rev. Urol. 2017, 14, 743–752. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pritchard-Jones, K.; Moroz, V.; Vujanić, G.; Powis, M.; Walker, J.; Messahel, B.; Hobson, R.; Levitt, G.; Kelsey, A.; Mitchell, C. Treatment and outcome of Wilms’ tumour patients: An analysis of all cases registered in the UKW3 trial. Ann. Oncol. 2012, 23, 2457–2463. [Google Scholar] [CrossRef] [PubMed]
- Koshinaga, T.; Takimoto, T.; Oue, T.; Okita, H.; Tanaka, Y.; Nozaki, M.; Tsuchiya, K.; Inoue, E.; Haruta, M.; Kaneko, Y.; et al. Outcome of renal tumors registered in Japan Wilms Tumor Study-2 (JWiTS-2): A report from the Japan Children’s Cancer Group (JCCG). Pediatr. Blood Cancer 2018, 65, 8. [Google Scholar] [CrossRef] [PubMed]
- Spreafico, F.; Biasoni, D.; Lo Vullo, S.; Gandola, L.; D’Angelo, P.; Terenziani, M.; Bianchi, M.; Provenzi, M.; Indolfi, P.; Pession, A.; et al. Results of the Third AIEOP Cooperative Protocol on Wilms Tumor (TW2003) and Related Considerations. J. Urol. 2017, 198, 1138–1145. [Google Scholar] [CrossRef] [PubMed]
- Reinhard, H.; Semler, O.; Bürger, D.; Bode, U.; Flentje, M.; Göbel, U.; Gutjahr, P.; Leuschner, I.; Maass, E.; Niggli, F.; et al. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor. Klin. Padiatr. 2004, 216, 132–140. [Google Scholar] [CrossRef] [PubMed]
- Kalapurakal, J.A.; Dome, J.S.; Perlman, E.J.; Malogolowkin, M.; Haase, G.M.; Grundy, P.; Coppes, M.J. Management of Wilms’ tumour: Current practice and future goals. Lancet Oncol. 2004, 5, 37–46. [Google Scholar] [CrossRef]
- Brok, J.; Treger, T.D.; Gooskens, S.L.; van den Heuvel-Eibrink, M.M.; Pritchard-Jones, K. Biology and treatment of renal tumours in childhood. Eur. J. Cancer 2016, 68, 179–195. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Davidoff, A.M. Wilms tumor. Adv. Pediatr. 2012, 59, 247–267. [Google Scholar] [CrossRef] [Green Version]
- Pritchard, J.; Imeson, J.; Barnes, J.; Cotterill, S.; Gough, D.; Marsden, H.B.; Morris-Jones, P.; Pearson, D. Results of the United Kingdom Children’s Cancer Study Group first Wilms’ Tumor Study. J. Clin. Oncol. 1995, 13, 124–133. [Google Scholar] [CrossRef]
- Mitchell, C.; Jones, P.M.; Kelsey, A.; Vujanic, G.M.; Marsden, B.; Shannon, R.; Gornall, P.; Owens, C.; Taylor, R.; Imeson, J.; et al. The treatment of Wilms’ tumour: Results of the United Kingdom Children’s cancer study group (UKCCSG) second Wilms’ tumour study. Br. J. Cancer 2000, 83, 602–608. [Google Scholar] [CrossRef] [PubMed]
- Mitchell, C.; Pritchard-Jones, K.; Shannon, R.; Hutton, C.; Stevens, S.; Machin, D.; Imeson, J.; Kelsey, A.; Vujanic, G.M.; Gornall, P.; et al. Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms’ tumour: Results of a randomised trial (UKW3) by the UK Children’s Cancer Study Group. Eur. J. Cancer 2006, 42, 2554–2562. [Google Scholar] [CrossRef]
- Oue, T.; Fukuzawa, M.; Okita, H.; Mugishima, H.; Horie, H.; Hata, J.-I.; Saito, M.; Nozaki, M.; Chin, M.; Nakadate, H.; et al. Outcome of pediatric renal tumor treated using the Japan Wilms Tumor Study-1 (JWiTS-1) protocol: A report from the JWiTS Group. Pediatr. Surg. Int. 2009, 25, 923–929. [Google Scholar] [CrossRef] [PubMed]
- Spreafico, F.; Gandola, L.; D’Angelo, P.; Terenziani, M.; Collini, P.; Bianchi, M.; Provenzi, M.; Indolfi, P.; Pession, A.; Nantron, M.; et al. Heterogeneity of disease classified as stage III in Wilms tumor: A report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Int. J. Radiat. Oncol. Biol. Phys. 2012, 82, 348–354. [Google Scholar] [CrossRef]
- Spreafico, F.; Gamba, B.; Mariani, L.; Collini, P.; D’Angelo, P.; Pession, A.; Di Cataldo, A.; Indolfi, P.; Nantron, M.; Terenziani, M.; et al. Loss of heterozygosity analysis at different chromosome regions in Wilms tumor confirms 1p allelic loss as a marker of worse prognosis: A study from the Italian Association of Pediatric Hematology and Oncology. J. Urol. 2013, 189, 260–266. [Google Scholar] [CrossRef] [PubMed]
- Spreafico, F.; Pritchard Jones, K.; Malogolowkin, M.H.; Bergeron, C.; Hale, J.; de Kraker, J.; Dallorso, S.; Acha, T.; de Camargo, B.; Dome, J.S.; et al. Treatment of relapsed Wilms tumors: Lessons learned. Expert Rev. Anticancer Ther. 2009, 9, 1807–1815. [Google Scholar] [CrossRef] [PubMed]
- Phelps, H.M.; Kaviany, S.; Borinstein, S.C.; Lovvorn, H.N., 3rd. Biological Drivers of Wilms Tumor Prognosis and Treatment. Children 2018, 5, 145. [Google Scholar] [CrossRef] [Green Version]
- Dávila Fajardo, R.; Furtwängler, R.; van Grotel, M.; van Tinteren, H.; Pasqualini, C.; Pritchard-Jones, K.; Al-Saadi, R.; de Camargo, B.; Ramírez Villar, G.L.; Graf, N.; et al. Outcome of Stage IV Completely Necrotic Wilms Tumour and Local Stage III Treated According to the SIOP 2001 Protocol. Cancers 2021, 13, 976. [Google Scholar] [CrossRef]
- Vujanić, G.M.; Sandstedt, B.; Harms, D.; Kelsey, A.; Leuschner, I.; de Kraker, J. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med. Pediatr. Oncol. 2002, 38, 79–82. [Google Scholar] [CrossRef]
- Breslow, N.; Sharples, K.; Beckwith, J.B.; Takashima, J.; Kelalis, P.P.; Green, D.M.; D’Angio, G.J. Prognostic factors in nonmetastatic, favorable histology Wilms’ tumor. Results of the Third National Wilms’ Tumor Study. Cancer 1991, 68, 2345–2353. [Google Scholar] [CrossRef]
- Grundy, P.E.; Breslow, N.E.; Li, S.; Perlman, E.; Beckwith, J.B.; Ritchey, M.L.; Shamberger, R.C.; Haase, G.M.; D’Angio, G.J.; Donaldson, M.; et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: A report from the National Wilms Tumor Study Group. J. Clin. Oncol. 2005, 23, 7312–7321. [Google Scholar] [CrossRef] [PubMed]
- Hol, J.A.; Lopez-Yurda, M.I.; Van Tinteren, H.; Van Grotel, M.; Godzinski, J.; Vujanic, G.; Oldenburger, F.; De Camargo, B.; Ramírez-Villar, G.L.; Bergeron, C.; et al. Prognostic significance of age in 5631 patients with Wilms tumour prospectively registered in International Society of Paediatric Oncology (SIOP) 93-01 and 2001. PLoS ONE 2019, 14, e0221373. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Irtan, S.; Van Tinteren, H.; Graf, N.; van den Heuvel-Eibrink, M.M.; Heij, H.; Bergeron, C.; de Camargo, B.; Acha, T.; Spreafico, F.; Vujanic, G.; et al. Evaluation of needle biopsy as a potential risk factor for local recurrence of Wilms tumour in the SIOP WT 2001 trial. Eur. J. Cancer 2019, 116, 13–20. [Google Scholar] [CrossRef]
- Weirich, A.; Ludwig, R.; Graf, N.; Abel, U.; Leuschner, I.; Vujanic, G.M.; Mehls, O.; Boos, J.; Beck, J.; Royer-Pokora, B.; et al. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity. Ann. Oncol. 2004, 15, 808–820. [Google Scholar] [CrossRef] [PubMed]
- Irtan, S.; Jitlal, M.; Bate, J.; Powis, M.; Vujanic, G.; Kelsey, A.; Walker, J.; Mitchell, C.; Machin, D.; Pritchard-Jones, K. Risk factors for local recurrence in Wilms tumour and the potential influence of biopsy—The United Kingdom experience. Eur. J. Cancer 2015, 51, 225–232. [Google Scholar] [CrossRef] [PubMed]
- Pritchard-Jones, K.; Kelsey, A.; Vujanic, G.; Imeson, J.; Hutton, C.; Mitchell, C. Older age is an adverse prognostic factor in stage I, favorable histology Wilms’ tumor treated with vincristine monochemotherapy: A study by the United Kingdom Children’s Cancer Study Group, Wilm’s Tumor Working Group. J. Clin. Oncol. 2003, 21, 3269–3275. [Google Scholar] [CrossRef]
- Chagtai, T.; Zill, C.; Dainese, L.; Wegert, J.; Savola, S.; Popov, S.; Mifsud, W.; Vujanic, G.; Sebire, N.; Le Bouc, Y.; et al. Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study. J. Clin. Oncol. 2016, 34, 3195–3203. [Google Scholar] [CrossRef] [PubMed]
- Perotti, D.; Spreafico, F.; Torri, F.; Gamba, B.; D’Adamo, P.; Pizzamiglio, S.; Terenziani, M.; Catania, S.; Collini, P.; Nantron, M.; et al. Genomic profiling by whole-genome single nucleotide polymorphism arrays in Wilms tumor and association with relapse. Genes Chromosomes Cancer 2012, 51, 644–653. [Google Scholar] [CrossRef]
- Gratias, E.J.; Dome, J.S.; Jennings, L.J.; Chi, Y.Y.; Tian, J.; Anderson, J.; Grundy, P.; Mullen, E.A.; Geller, J.I.; Fernandez, C.V.; et al. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children’s Oncology Group. J. Clin. Oncol. 2016, 34, 3189–3194. [Google Scholar] [CrossRef]
- Vujanic, G.M.; Gessler, M.; Ooms, A.; Collini, P.; Coulomb-l’Hermine, A.; D’Hooghe, E.; de Krijger, R.R.; Perotti, D.; Pritchard-Jones, K.; Vokuhl, C.; et al. The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol. Nat. Rev. Urol. 2018, 15, 693–701. [Google Scholar] [CrossRef] [Green Version]
- Nelson, M.V.; van den Heuvel-Eibrink, M.M.; Graf, N.; Dome, J.S. New approaches to risk stratification for Wilms tumor. Curr. Opin. Pediatr. 2021, 33, 40–48. [Google Scholar] [CrossRef]
- Perlman, E.; Grundy, P.; Anderson, J.; Jennings, L.; Green, D.; Dome, J.; Shamberger, R.; Ruteshouser, E.; Huff, V.D. WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: A children’s oncology group study. J. Clin. Oncol. 2011, 29, 698–703. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Haruta, M.; Arai, Y.; Okita, H.; Tanaka, Y.; Takimoto, T.; Sugino, R.P.; Yamada, Y.; Kamijo, T.; Oue, T.; Fukuzawa, M.; et al. Combined Genetic and Chromosomal Characterization of Wilms Tumors Identifies Chromosome 12 Gain as a Potential New Marker Predicting a Favorable Outcome. Neoplasia 2019, 21, 117–131. [Google Scholar] [CrossRef]
- Fernandez, C.V.; Mullen, E.A.; Chi, Y.Y.; Ehrlich, P.F.; Perlman, E.J.; Kalapurakal, J.A.; Khanna, G.; Paulino, A.C.; Hamilton, T.E.; Gow, K.W.; et al. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children’s Oncology Group Study AREN0532. J. Clin. Oncol. 2018, 36, 254–261. [Google Scholar] [CrossRef] [PubMed]
- Dome, J.S.; Perlman, E.J.; Graf, N. Risk stratification for wilms tumor: Current approach and future directions. In American Society of Clinical Oncology Educational Book; American Society of Clinical Oncology: Alexandria, VA, USA, 2014; Volume 34. [Google Scholar] [CrossRef]
- Israels, T.; Moreira, C.; Scanlan, T.; Molyneux, L.; Kampondeni, S.; Hesseling, P.; Heij, H.; Borgstein, E.; Vujanic, G.; Pritchard-Jones, K.; et al. SIOP PODC: Clinical guidelines for the management of children with Wilms tumour in a low income setting. Pediatr. Blood Cancer 2013, 60, 5–11. [Google Scholar] [CrossRef] [PubMed]
- Pritchard-Jones, K.; Bergeron, C.; de Camargo, B.; van den Heuvel-Eibrink, M.M.; Acha, T.; Godzinski, J.; Oldenburger, F.; Boccon-Gibod, L.; Leuschner, I.; Vujanic, G.; et al. Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms’ tumour (SIOP WT 2001): An open-label, non-inferiority, randomised controlled trial. Lancet 2015, 386, 1156–1164. [Google Scholar] [CrossRef] [Green Version]
- Green, D.M.; Breslow, N.E.; Beckwith, J.B.; Finklestein, J.Z.; Grundy, P.E.; Thomas, P.R.; Kim, T.; Shochat, S.J.; Haase, G.M.; Ritchey, M.L.; et al. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms’ tumor: A report from the National Wilms’ Tumor Study Group. J. Clin. Oncol. 1998, 16, 237–245. [Google Scholar] [CrossRef]
- Jereb, B.; Tournade, M.F.; Lemerle, J.; Voûte, P.A.; Delemarre, J.F.; Ahstrom, L.; Flamant, R.; Gérard-Marchant, R.; Sandstedt, B. Lymph node invasion and prognosis in nephroblastoma. Cancer 1980, 45, 1632–1636. [Google Scholar] [CrossRef]
- Shamberger, R.C.; Ritchey, M.L.; Haase, G.M.; Bergemann, T.L.; Loechelt-Yoshioka, T.; Breslow, N.E.; Green, D.M. Intravascular extension of Wilms tumor. Ann. Surg. 2001, 234, 116–121. [Google Scholar] [CrossRef]
- Lall, A.; Pritchard-Jones, K.; Walker, J.; Hutton, C.; Stevens, S.; Azmy, A.; Carachi, R. Wilms’ tumor with intracaval thrombus in the UK Children’s Cancer Study Group UKW3 trial. J. Pediatr. Surg. 2006, 41, 382–387. [Google Scholar] [CrossRef]
- Dix, D.B.; Fernandez, C.V.; Chi, Y.-Y.; Mullen, E.A.; Geller, J.I.; Gratias, E.J.; Khanna, G.; Kalapurakal, J.A.; Perlman, E.J.; Seibel, N.L.; et al. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children’s Oncology Group AREN0532 and AREN0533 Study Report. J. Clin. Oncol. 2019, 37, 2769–2777. [Google Scholar] [CrossRef]
- Daw, N.C.; Chi, Y.-Y.; Kalapurakal, J.A.; Kim, Y.; Hoffer, F.A.; Geller, J.I.; Perlman, E.J.; Ehrlich, P.F.; Mullen, E.A.; Warwick, A.B.; et al. Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children’s Oncology Group AREN0321 Study. J. Clin. Oncol. 2020, 38, 1558–1568. [Google Scholar] [CrossRef]
- Dome, J.S.; Cotton, C.A.; Perlman, E.J.; Breslow, N.E.; Kalapurakal, J.A.; Ritchey, M.L.; Grundy, P.E.; Malogolowkin, M.; Beckwith, J.B.; Shamberger, R.C.; et al. Treatment of Anaplastic Histology Wilms’ Tumor: Results From the Fifth National Wilms’ Tumor Study. J. Clin. Oncol. 2006, 24, 2352–2358. [Google Scholar] [CrossRef]
- Green, D.M.; Beckwith, J.B.; Breslow, N.E.; Faria, P.; Moksness, J.; Finklestein, J.Z.; Grundy, P.; Thomas, P.R.; Kim, T.; Shochat, S.; et al. Treatment of children with stages II to IV anaplastic Wilms’ tumor: A report from the National Wilms’ Tumor Study Group. J. Clin. Oncol. 1994, 12, 2126–2131. [Google Scholar] [CrossRef]
- Messahel, B.; Williams, R.; Ridolfi, A.; A’Hern, R.; Warren, W.; Tinworth, L.; Hobson, R.; Al-Saadi, R.; Whyman, G.; Brundler, M.A.; et al. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: A Children’s Cancer and Leukaemia Group (CCLG) Study. Eur. J. Cancer 2009, 45, 819–826. [Google Scholar] [CrossRef] [PubMed]
- Segers, H.; van den Heuvel-Eibrink, M.M.; Williams, R.D.; van Tinteren, H.; Vujanic, G.; Pieters, R.; Pritchard-Jones, K.; Bown, N. Gain of 1q is a marker of poor prognosis in Wilms’ tumors. Genes Chromosomes Cancer 2013, 52, 1065–1074. [Google Scholar] [CrossRef] [PubMed]
- Graf, N.; van Tinteren, H.; Bergeron, C.; Pein, F.; van den Heuvel-Eibrink, M.M.; Sandstedt, B.; Schenk, J.P.; Godzinski, J.; Oldenburger, F.; Furtwängler, R.; et al. Characteristics and outcome of stage II and III non-anaplastic Wilms’ tumour treated according to the SIOP trial and study 93-01. Eur. J. Cancer 2012, 48, 3240–3248. [Google Scholar] [CrossRef] [PubMed]
- Grundy, P.; Tinteren, H.; Anderson, J.; Dome, J.; Graf, N.; Pritchard-Jones, K. SIGNIFICANCE OF LYMPH NODE INVOLVEMENT IN NEPHROBLASTOMA. Pediatr. Blood Cancer 2010, 55, 822–823. [Google Scholar]
- Ehrlich, P.F.; Anderson, J.R.; Ritchey, M.L.; Dome, J.S.; Green, D.M.; Grundy, P.E.; Perlman, E.J.; Kalapurakal, J.A.; Breslow, N.E.; Shamberger, R.C. Clinicopathologic findings predictive of relapse in children with stage III favorable-histology Wilms tumor. J. Clin. Oncol. 2013, 31, 1196–1201. [Google Scholar] [CrossRef] [Green Version]
- Irtan, S.; Messahel, B.; Moroz, V.; Taylor, R.E.; Grundy, R.; Kelsey, A.; Vujanic, G.; Pritchard-Jones, K. Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial. Radiother. Oncol. 2019, 131, 1–7. [Google Scholar] [CrossRef]
- Shamberger, R.C.; Guthrie, K.A.; Ritchey, M.L.; Haase, G.M.; Takashima, J.; Beckwith, J.B.; D’Angio, G.J.; Green, D.M.; Breslow, N.E. Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4. Ann. Surg. 1999, 229, 292–297. [Google Scholar] [CrossRef]
- Kieran, K.; Anderson, J.R.; Dome, J.S.; Ehrlich, P.F.; Ritchey, M.L.; Shamberger, R.C.; Perlman, E.J.; Green, D.M.; Davidoff, A.M. Lymph node involvement in Wilms tumor: Results from National Wilms Tumor Studies 4 and 5. J. Pediatr. Surg. 2012, 47, 700–706. [Google Scholar] [CrossRef] [Green Version]
- Tugnait, S.; Al-Saadi, R.; Williams, R.; Oostveen, R.; Brok, J.; Weeks, M.; Bate, J.; Chowdhury, T.; Irtan, S.; Pavasovic, V.; et al. Adherence to LymphNode Sampling Recommendations in WilmsTumours Registered in the SIOP WT 2001 andImport Studies in the UK and Ireland. Pediatr. Blood Cancer 2019, 66, s89. [Google Scholar] [CrossRef]
- Green, D.M.; Breslow, N.E.; D’Angio, G.J.; Malogolowkin, M.H.; Ritchey, M.L.; Evans, A.E.; Beckwith, J.B.; Perlman, E.J.; Shamberger, R.C.; Peterson, S.; et al. Outcome of patients with Stage II/favorable histology Wilms tumor with and without local tumor spill: A report from the National Wilms Tumor Study Group. Pediatr. Blood Cancer 2014, 61, 134–139. [Google Scholar] [CrossRef] [Green Version]
- Gow, K.W.; Barnhart, D.C.; Hamilton, T.E.; Kandel, J.J.; Chen, M.K.S.; Ferrer, F.A.; Price, M.R.; Mullen, E.A.; Geller, J.I.; Gratias, E.J.; et al. Primary nephrectomy and intraoperative tumor spill: Report from the Children’s Oncology Group (COG) renal tumors committee. J. Pediatr. Surg. 2013, 48, 34–38. [Google Scholar] [CrossRef] [Green Version]
- Ora, I.; van Tinteren, H.; Bergeron, C.; de Kraker, J. Progression of localised Wilms’ tumour during preoperative chemotherapy is an independent prognostic factor: A report from the SIOP 93-01 nephroblastoma trial and study. Eur. J. Cancer 2007, 43, 131–136. [Google Scholar] [CrossRef]
- Graf, N.; Furtwängler, R. Preoperative chemotherapy and local stage III in nephroblastoma. Transl. Pediatr. 2014, 3, 4–11. [Google Scholar] [CrossRef]
- Vujanić, G.M.; Kelsey, A.; Mitchell, C.; Shannon, R.S.; Gornall, P. The role of biopsy in the diagnosis of renal tumors of childhood: Results of the UKCCSG Wilms tumor study 3. Med. Pediatr. Oncol. 2003, 40, 18–22. [Google Scholar] [CrossRef]
- Verschuur, A.; Tinteren, H.V.; Graf, N.; Bergeron, C.; Sandstedt, B.; de Kraker, J. Treatment of Pulmonary Metastases in Children With Stage IV Nephroblastoma With Risk-Based Use of Pulmonary Radiotherapy. J. Clin. Oncol. 2012, 30, 3533–3539. [Google Scholar] [CrossRef]
- Verschuur, A.; Furtwangler, R.; Pasqualini, C.; Lopez, M.; Van Tinteren, H.; Howell, L.; Ramirez-Villar, G.; Bergeron, C.; Spreafico, F.; De Camargo, B.; et al. Treatment and outcome of children with stage iv nephroblastoma identifying new risk categories; Results of SIOP 2001 protocol. Pediatr. Blood Cancer 2018, 65 (Suppl. 2), S22–S23. [Google Scholar]
- Pasqualini, C.; Furtwängler, R.; van Tinteren, H.; Teixeira, R.A.P.; Acha, T.; Howell, L.; Vujanic, G.; Godzinski, J.; Melchior, P.; Smets, A.M.; et al. Outcome of patients with stage IV high-risk Wilms tumour treated according to the SIOP2001 protocol: A report of the SIOP Renal Tumour Study Group. Eur. J. Cancer 2020, 128, 38–46. [Google Scholar] [CrossRef] [PubMed]
- Ehrlich, P.F.; Ferrer, F.A.; Ritchey, M.L.; Anderson, J.R.; Green, D.M.; Grundy, P.E.; Dome, J.S.; Kalapurakal, J.A.; Perlman, E.J.; Shamberger, R.C. Hepatic metastasis at diagnosis in patients with Wilms tumor is not an independent adverse prognostic factor for stage IV Wilms tumor: A report from the Children’s Oncology Group/National Wilms Tumor Study Group. Ann. Surg. 2009, 250, 642–648. [Google Scholar] [CrossRef] [Green Version]
- Dix, D.B.; Seibel, N.L.; Chi, Y.-Y.; Khanna, G.; Gratias, E.; Anderson, J.R.; Mullen, E.A.; Geller, J.I.; Kalapurakal, J.A.; Paulino, A.C.; et al. Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children’s Oncology Group AREN0533 Study. J. Clin. Oncol. 2018, 36, 1564–1570. [Google Scholar] [CrossRef] [PubMed]
- Warmann, S.W.; Furtwängler, R.; Blumenstock, G.; Armeanu, S.; Nourkami, N.; Leuschner, I.; Schenk, J.P.; Graf, N.; Fuchs, J. Tumor biology influences the prognosis of nephroblastoma patients with primary pulmonary metastases: Results from SIOP 93-01/GPOH and SIOP 2001/GPOH. Ann. Surg. 2011, 254, 155–162. [Google Scholar] [CrossRef] [PubMed]
- Grundy, P.E.; Green, D.M.; Dirks, A.C.; Berendt, A.E.; Breslow, N.E.; Anderson, J.R.; Dome, J.S. Clinical significance of pulmonary nodules detected by CT and Not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and -5: A report from the Children’s Oncology Group. Pediatr. Blood Cancer 2012, 59, 631–635. [Google Scholar] [CrossRef] [Green Version]
- Smets, A.M.J.B.; Tinteren, H.V.; Bergeron, C.; Camargo, B.D.; Graf, N.; Pritchard-Jones, K.; Kraker, J.D. The contribution of chest CT-scan at diagnosis in children with unilateral Wilms’ tumour. Results of the SIOP 2001 study. Eur. J. Cancer 2012, 48, 1060–1065. [Google Scholar] [CrossRef]
- Ehrlich, P.; Chi, Y.Y.; Chintagumpala, M.M.; Hoffer, F.A.; Perlman, E.J.; Kalapurakal, J.A.; Warwick, A.; Shamberger, R.C.; Khanna, G.; Hamilton, T.E.; et al. Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534): A Report From the Children’s Oncology Group. Ann. Surg. 2017, 266, 470–478. [Google Scholar] [CrossRef] [Green Version]
- Indolfi, P.; Jenkner, A.; Terenziani, M.; Crocoli, A.; Serra, A.; Collini, P.; Biasoni, D.; Gandola, L.; Bisogno, G.; Cecchetto, G.; et al. Synchronous bilateral Wilms tumor. Cancer 2013, 119, 1586–1592. [Google Scholar] [CrossRef]
- Hamilton, T.E.; Ritchey, M.L.; Haase, G.M.; Argani, P.; Peterson, S.M.; Anderson, J.R.; Green, D.M.; Shamberger, R.C. The management of synchronous bilateral Wilms tumor: A report from the National Wilms Tumor Study Group. Ann. Surg. 2011, 253, 1004–1010. [Google Scholar] [CrossRef] [Green Version]
- Oue, T.; Koshinaga, T.; Okita, H.; Kaneko, Y.; Hinotsu, S.; Fukuzawa, M. Bilateral Wilms tumors treated according to the Japan Wilms Tumor Study Group protocol. Pediatr. Blood Cancer 2014, 61, 1184–1189. [Google Scholar] [CrossRef]
- Sudour, H.; Audry, G.; Schleimacher, G.; Patte, C.; Dussart, S.; Bergeron, C. Bilateral Wilms tumors (WT) treated with the SIOP 93 protocol in France: Epidemiological survey and patient outcome. Pediatr. Blood Cancer 2012, 59, 57–61. [Google Scholar] [CrossRef]
- Furtwängler, R.; Schmolze, M.; Gräber, S.; Leuschner, I.; Amann, G.; Schenk, J.P.; Niggli, F.; Kager, L.; von Schweinitz, D.; Graf, N. Pretreatment for bilateral nephroblastomatosis is an independent risk factor for progressive disease in patients with stage V nephroblastoma. Klin. Padiatr. 2014, 226, 175–181. [Google Scholar] [CrossRef]
- Charlton, J.; Irtan, S.; Bergeron, C.; Pritchard-Jones, K. Bilateral Wilms tumour: A review of clinical and molecular features. Expert Rev. Mol. Med. 2017, 19, e8. [Google Scholar] [CrossRef]
- Beckwith, J.B.; Palmer, N.F. Histopathology and prognosis of Wilms tumors: Results from the First National Wilms’ Tumor Study. Cancer 1978, 41, 1937–1948. [Google Scholar] [CrossRef]
- Faria, P.; Beckwith, J.B.; Mishra, K.; Zuppan, C.; Weeks, D.A.; Breslow, N.; Green, D.M. Focal Versus Diffuse Anaplasia in Wilms Tumor—New Definitions with Prognostic Significance: A Report from the National Wilms Tumor Study Group. Am. J. Surg. Pathol. 1996, 20, 909–920. [Google Scholar] [CrossRef]
- Vujanić, G.M.; Harms, D.; Sandstedt, B.; Weirich, A.; de Kraker, J.; Delemarre, J.F.M. New definitions of focal and diffuse anaplasia in Wilms tumor: The International Society of Paediatric Oncology (SIOP) experience. Med. Pediatr. Oncol. 1999, 32, 317–323. [Google Scholar] [CrossRef]
- Williams, R.D.; Chagtai, T.; Alcaide-German, M.; Apps, J.; Wegert, J.; Popov, S.; Vujanic, G.; van Tinteren, H.; van den Heuvel-Eibrink, M.M.; Kool, M.; et al. Multiple mechanisms of MYCN dysregulation in Wilms tumour. Oncotarget 2015, 6, 7232–7243. [Google Scholar] [CrossRef] [Green Version]
- Bardeesy, N.; Falkoff, D.; Petruzzi, M.J.; Nowak, N.; Zabel, B.; Adam, M.; Aguiar, M.C.; Grundy, P.; Shows, T.; Pelletier, J. Anaplastic Wilms’ tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat. Genet. 1994, 7, 91–97. [Google Scholar] [CrossRef]
- Bardeesy, N.; Beckwith, J.B.; Pelletier, J. Clonal expansion and attenuated apoptosis in Wilms’ tumors are associated with p53 gene mutations. Cancer Res. 1995, 55, 215–219. [Google Scholar]
- Maschietto, M.; Williams, R.D.; Chagtai, T.; Popov, S.D.; Sebire, N.J.; Vujanic, G.; Perlman, E.; Anderson, J.R.; Grundy, P.; Dome, J.S.; et al. TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia. PLoS ONE 2014, 9, e109924. [Google Scholar] [CrossRef]
- Ooms, A.H.; Gadd, S.; Gerhard, D.S.; Smith, M.A.; Guidry Auvil, J.M.; Meerzaman, D.; Chen, Q.R.; Hsu, C.H.; Yan, C.; Nguyen, C.; et al. Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children’s Oncology Group. Clin. Cancer Res. 2016, 22, 5582–5591. [Google Scholar] [CrossRef] [Green Version]
- Van den Heuvel-Eibrink, M.M.; van Tinteren, H.; Bergeron, C.; Coulomb-L’Hermine, A.; de Camargo, B.; Leuschner, I.; Sandstedt, B.; Acha, T.; Godzinski, J.; Oldenburger, F.; et al. Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG). Eur. J. Cancer 2015, 51, 498–506. [Google Scholar] [CrossRef]
- Treger, T.D.; Chowdhury, T.; Pritchard-Jones, K.; Behjati, S. The genetic changes of Wilms tumour. Nat. Rev. Nephrol. 2019, 15, 240–251. [Google Scholar] [CrossRef]
- Beckwith, J.B.; Zuppan, C.E.; Browning, N.G.; Moksness, J.; Breslow, N.E. Histological analysis of aggressiveness and responsiveness in Wilms’ tumor. Med. Pediatr. Oncol. 1996, 27, 422–428. [Google Scholar] [CrossRef]
- Weirich, A.; Leuschner, I.; Harms, D.; Vujanic, G.M.; Troger, J.; Abel, U.; Graf, N.; Schmidt, D.; Ludwig, R.; Voute, P.A. Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH. Ann. Oncol. 2001, 12, 311–319. [Google Scholar] [CrossRef]
- Graf, N.; Tinteren, H.; Pritchard-Jones, K.; Bergeron, C.; Sandstedt, B.; Leuschner, I.; Vujanic, G.; Boccon-Gibod, L.; Heuvel-Eibrink, M.; Camargo, B.; et al. Is the absolute blastema volume after preoperative chemotherapy in nephroblastoma relevant for prognosis? Pediatr. Blood Cancer 2011, 57, 741–742. [Google Scholar]
- Boccon-Gibod, L.; Rey, A.; Sandstedt, B.; Delemarre, J.; Harms, D.; Vujanic, G.; De Kraker, J.; Weirich, A.; Tournade, M.-F. Complete necrosis induced by preoperative chemotherapy in Wilms tumor as an indicator of low risk: Report of the International Society of Paediatric Oncology (SIOP) Nephroblastoma Trial and Study 9. Med. Pediatr. Oncol. 2000, 34, 183–190. [Google Scholar] [CrossRef]
- Verschuur, A.C.; Vujanic, G.M.; Van Tinteren, H.; Jones, K.P.; de Kraker, J.; Sandstedt, B. Stromal and Epithelial Predominant Wilms Tumours Have an Excellent Outcome: The SIOP 93 01 Experience. Pediatr. Blood Cancer 2010, 55, 233–238. [Google Scholar] [CrossRef]
- Royer-Pokora, B.; Beier, M.; Brandt, A.; Duhme, C.; Busch, M.; de Torres, C.; Royer, H.-D.; Mora, J. Chemotherapy and terminal skeletal muscle differentiation in WT1-mutant Wilms tumors. Cancer Med. 2018, 7, 1359–1368. [Google Scholar] [CrossRef] [Green Version]
- Royer-Pokora, B.; Weirich, A.; Schumacher, V.; Uschkereit, C.; Beier, M.; Leuschner, I.; Graf, N.; Autschbach, F.; Schneider, D.; von Harrach, M. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein β1 gene CTNNB1 for patients with Wilms tumors. Cancer 2008, 113, 1080–1089. [Google Scholar] [CrossRef]
- Larsen, E.; Perez-Atayde, A.; Green, D.M.; Retik, A.; Clavell, L.A.; Sallan, S.E. Surgery only for the treatment of patients with stage I (Cassady) Wilms’ tumor. Cancer 1990, 66, 264–266. [Google Scholar] [CrossRef]
- Green, D.M.; Breslow, N.E.; Beckwith, J.B.; Takashima, J.; Kelalis, P.; D’Angio, G.J. Treatment outcomes in patients less than 2 years of age with small, stage I, favorable-histology Wilms’ tumors: A report from the National Wilms’ Tumor Study. J. Clin. Oncol. 1993, 11, 91–95. [Google Scholar] [CrossRef]
- Dome, J.S.; Huff, V. Wilms Tumor Predisposition. In GeneReviews®; Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Mirzaa, G., Amemiya, A., Eds.; University of Washington: Seattle, WA, USA, 1993. [Google Scholar]
- Segers, H.; Kersseboom, R.; Alders, M.; Pieters, R.; Wagner, A.; van den Heuvel-Eibrink, M.M. Frequency of WT1 and 11p15 constitutional aberrations and phenotypic correlation in childhood Wilms tumour patients. Eur. J. Cancer 2012, 48, 3249–3256. [Google Scholar] [CrossRef]
- Dumoucel, S.; Gauthier-Villars, M.; Stoppa-Lyonnet, D.; Parisot, P.; Brisse, H.; Philippe-Chomette, P.; Sarnacki, S.; Boccon-Gibod, L.; Rossignol, S.; Baumann, C.; et al. Malformations, genetic abnormalities, and Wilms tumor. Pediatr. Blood Cancer 2014, 61, 140–144. [Google Scholar] [CrossRef] [PubMed]
- Merks, J.H.M.; Caron, H.N.; Hennekam, R.C.M. High incidence of malformation syndromes in a series of 1073 children with cancer. Am. J. Med. Genet. Part A 2005, 134, 132–143. [Google Scholar] [CrossRef]
- Gadd, S.; Huff, V.; Walz, A.L.; Ooms, A.H.A.G.; Armstrong, A.E.; Gerhard, D.S.; Smith, M.A.; Auvil, J.M.G.; Meerzaman, D.; Chen, Q.-R.; et al. A Children’s Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. Nat. Genet. 2017, 49, 1487–1494. [Google Scholar] [CrossRef] [Green Version]
- Hol, J.A.; Jongmans, M.C.J.; Sudour-Bonnange, H.; Ramírez-Villar, G.L.; Chowdhury, T.; Rechnitzer, C.; Pal, N.; Schleiermacher, G.; Karow, A.; Kuiper, R.P.; et al. Clinical characteristics and outcomes of children with WAGR syndrome and Wilms tumor and/or nephroblastomatosis: The 30-year SIOP-RTSG experience. Cancer 2020, 127. [Google Scholar] [CrossRef]
- Breslow, N.E.; Norris, R.; Norkool, P.A.; Kang, T.; Beckwith, J.B.; Perlman, E.J.; Ritchey, M.L.; Green, D.M.; Nichols, K.E. Characteristics and outcomes of children with the Wilms tumor-Aniridia syndrome: A report from the National Wilms Tumor Study Group. J. Clin. Oncol. 2003, 21, 4579–4585. [Google Scholar] [CrossRef]
- Porteus, M.H.; Narkool, P.; Neuberg, D.; Guthrie, K.; Breslow, N.; Green, D.M.; Diller, L. Characteristics and outcome of children with Beckwith-Wiedemann syndrome and Wilms’ tumor: A report from the National Wilms Tumor Study Group. J. Clin. Oncol. 2000, 18, 2026–2031. [Google Scholar] [CrossRef]
- Mahamdallie, S.S.; Hanks, S.; Karlin, K.L.; Zachariou, A.; Perdeaux, E.R.; Ruark, E.; Shaw, C.A.; Renwick, A.; Ramsay, E.; Yost, S.; et al. Mutations in the transcriptional repressor REST predispose to Wilms tumor. Nat. Genet. 2015, 47, 1471–1474. [Google Scholar] [CrossRef]
- Diets, I.J.; Hoyer, J.; Ekici, A.B.; Popp, B.; Hoogerbrugge, N.; van Reijmersdal, S.V.; Bhaskaran, R.; Hadjihannas, M.; Vasileiou, G.; Thiel, C.T.; et al. TRIM28 haploinsufficiency predisposes to Wilms tumor. Int. J. Cancer 2019, 145, 941–951. [Google Scholar] [CrossRef] [Green Version]
- Hol, J.; Diets, I.; Krijger, R.; Heuvel-Eibrink, M.; Jongmans, M.; Kuiper, R. TRIM28 variants and Wilms’ tumour predisposition. J. Pathol. 2021, 254, 494–504. [Google Scholar] [CrossRef]
- Armstrong, A.E.; Gadd, S.; Huff, V.; Gerhard, D.S.; Dome, J.S.; Perlman, E.J. A unique subset of low-risk Wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A Children’s Oncology Group study. PLoS ONE 2018, 13, e0208936. [Google Scholar] [CrossRef] [Green Version]
- Halliday, B.J.; Fukuzawa, R.; Markie, D.M.; Grundy, R.G.; Ludgate, J.L.; Black, M.A.; Skeen, J.E.; Weeks, R.J.; Catchpoole, D.R.; Roberts, A.G.K.; et al. Germline mutations and somatic inactivation of TRIM28 in Wilms tumour. PLoS Genet. 2018, 14, e1007399. [Google Scholar] [CrossRef]
- Parsons, L.N.; Mullen, E.A.; Geller, J.I.; Chi, Y.Y.; Khanna, G.; Glick, R.D.; Aldrink, J.H.; Vallance, K.L.; Kim, Y.; Fernandez, C.V.; et al. Outcome analysis of stage I epithelial-predominant favorable-histology Wilms tumors: A report from Children’s Oncology Group study AREN03B2. Cancer 2020, 126, 2866–2871. [Google Scholar] [CrossRef]
- Gessler, M.; Graf, N. Less may be more for stage I epithelial Wilms tumors. Cancer 2020, 126, 2762–2764. [Google Scholar] [CrossRef]
- Gadd, S.; Huff, V.; Huang, C.C.; Ruteshouser, E.C.; Dome, J.S.; Grundy, P.E.; Breslow, N.; Jennings, L.; Green, D.M.; Beckwith, J.B.; et al. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: A Children’s Oncology Group Study. Neoplasia 2012, 14, 742–756. [Google Scholar] [CrossRef] [Green Version]
- Little, S.; King-Underwood, L.; Hing, S.; Sodha, N.; Menghitsu, T.; Warren, W.; Grundy, P.; Pritchard-Jones, K. Somatic mutations in the WT1 and p53 genes and Wilms’ tumor relapse. Cancer Res. 2004, 64, 627–628. [Google Scholar]
- Fernandez, C.V.; Perlman, E.J.; Mullen, E.A.; Chi, Y.Y.; Hamilton, T.E.; Gow, K.W.; Ferrer, F.A.; Barnhart, D.C.; Ehrlich, P.F.; Khanna, G.; et al. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children’s Oncology Group AREN0532. Ann. Surg. 2017, 265, 835–840. [Google Scholar] [CrossRef]
- Charlton, J.; Williams, R.D.; Sebire, N.J.; Popov, S.; Vujanic, G.; Chagtai, T.; Alcaide-German, M.; Morris, T.; Butcher, L.M.; Guilhamon, P.; et al. Comparative methylome analysis identifies new tumour subtypes and biomarkers for transformation of nephrogenic rests into Wilms tumour. Genome Med. 2015, 7, 11. [Google Scholar] [CrossRef] [Green Version]
- Okamoto, K.; Morison, I.M.; Taniguchi, T.; Reeve, A.E. Epigenetic changes at the insulin-like growth factor II/H19 locus in developing kidney is an early event in Wilms tumorigenesis. Proc. Natl. Acad. Sci. USA 1997, 94, 5367–5371. [Google Scholar] [CrossRef] [Green Version]
- Coorens, T.H.H.; Treger, T.D.; Al-Saadi, R.; Moore, L.; Tran, M.G.B.; Mitchell, T.J.; Tugnait, S.; Thevanesan, C.; Young, M.D.; Oliver, T.R.W.; et al. Embryonal precursors of Wilms tumor. Science 2019, 366, 1247–1251. [Google Scholar] [CrossRef]
- Major, M.B.; Camp, N.D.; Berndt, J.D.; Yi, X.; Goldenberg, S.J.; Hubbert, C.; Biechele, T.L.; Gingras, A.C.; Zheng, N.; Maccoss, M.J.; et al. Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science 2007, 316, 1043–1046. [Google Scholar] [CrossRef]
- Walz, A.L.; Ooms, A.; Gadd, S.; Gerhard, D.S.; Smith, M.A.; Guidry Auvil, J.M.; Meerzaman, D.; Chen, Q.-R.; Hsu, C.H.; Yan, C.; et al. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell 2015, 27, 286–297. [Google Scholar] [CrossRef] [Green Version]
- Wegert, J.; Ishaque, N.; Vardapour, R.; Geörg, C.; Gu, Z.; Bieg, M.; Ziegler, B.; Bausenwein, S.; Nourkami, N.; Ludwig, N.; et al. Mutations in the SIX1/2 Pathway and the DROSHA/DGCR8 miRNA Microprocessor Complex Underlie High-Risk Blastemal Type Wilms Tumors. Cancer Cell 2015, 27, 298–311. [Google Scholar] [CrossRef] [Green Version]
- Spreafico, F.; Ciceri, S.; Gamba, B.; Torri, F.; Terenziani, M.; Collini, P.; Macciardi, F.; Radice, P.; Perotti, D. Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences. Oncotarget 2016, 7, 8908–8915. [Google Scholar] [CrossRef] [Green Version]
- Ciceri, S.; Montalvão-de-Azevedo, R.; Tajbakhsh, A.; Bertolotti, A.; Spagnuolo, R.D.; Boschetti, L.; Capasso, M.; D’Angelo, P.; Serra, A.; Diomedi-Camassei, F.; et al. Analysis of the mutational status of SIX1/2 and microRNA processing genes in paired primary and relapsed Wilms tumors and association with relapse. Cancer Gene Ther. 2020. [Google Scholar] [CrossRef]
- Dome, J.S.; Fernandez, C.V.; Mullen, E.A.; Kalapurakal, J.A.; Geller, J.I.; Huff, V.; Gratias, E.J.; Dix, D.B.; Ehrlich, P.F.; Khanna, G.; et al. Children’s Oncology Group’s 2013 blueprint for research: Renal tumors. Pediatr. Blood Cancer 2013, 60, 994–1000. [Google Scholar] [CrossRef] [Green Version]
- Graf, N.; Tournade, M.-F.; de Kraker, J. THE ROLE OF PREOPERATIVE CHEMOTHERAPY IN THE MANAGEMENT OF WILMS’ TUMOR: The SIOP Studies. Urol. Clin. N. Am. 2000, 27, 443–454. [Google Scholar] [CrossRef]
- Godzinski, J.; Tournade, M.F.; deKraker, J.; Lemerle, J.; Voute, P.A.; Weirich, A.; Ludwig, R.; Rapala, M.; Skotnicka, G.; Gauthier, F.; et al. Rarity of surgical complications after postchemotherapy nephrectomy for nephroblastoma. Experience of the International Society of Paediatric Oncology-Trial and Study “SIOP-9”. International Society of Paediatric Oncology Nephroblastoma Trial and Study Committee. Eur. J. Pediatr. Surg. 1998, 8, 83–86. [Google Scholar] [CrossRef]
- D’Angio, G.J. Pre-or Postoperative Therapy for Wilms’ Tumor? J. Clin. Oncol. 2008, 26, 4055–4057. [Google Scholar] [CrossRef]
- Spreafico, F.; Bellani, F.F. Wilms’ tumor: Past, present and (possibly) future. Expert Rev. Anticancer Ther. 2006, 6, 249–258. [Google Scholar] [CrossRef]
- Breslow, N.E.; Ou, S.S.; Beckwith, J.B.; Haase, G.M.; Kalapurakal, J.A.; Ritchey, M.L.; Shamberger, R.C.; Thomas, P.R.; D’Angio, G.J.; Green, D.M. Doxorubicin for favorable histology, Stage II-III Wilms tumor: Results from the National Wilms Tumor Studies. Cancer 2004, 101, 1072–1080. [Google Scholar] [CrossRef] [PubMed]
- Daw, N.C.; Chi, Y.-Y.; Kim, Y.; Mullen, E.A.; Kalapurakal, J.A.; Tian, J.; Khanna, G.; Geller, J.I.; Perlman, E.J.; Ehrlich, P.F.; et al. Treatment of stage I anaplastic Wilms’ tumour: A report from the Children’s Oncology Group AREN0321 study. Eur. J. Cancer 2019, 118, 58–66. [Google Scholar] [CrossRef]
- Fajardo, R.D.; van den Heuvel-Eibrink, M.M.; van Tinteren, H.; Spreafico, F.; Acha, T.; Bergeron, C.; de Camargo, B.; Oldenburger, F.; Rübe, C.; Oue, T.; et al. Is radiotherapy required in first-line treatment of stage I diffuse anaplastic Wilms tumor? A report of SIOP-RTSG, AIEOP, JWiTS, and UKCCSG. Pediatr. Blood Cancer 2020, 67, e28039. [Google Scholar] [CrossRef]
- Dávila Fajardo, R.; Oldenburger, E.; Rübe, C.; López-Yurda, M.; Pritchard-Jones, K.; Bergeron, C.; Graf, N.; van Grotel, M.; van Tinteren, H.; Saunders, D.; et al. Evaluation of boost irradiation in patients with intermediate-risk stage III Wilms tumour with positive lymph nodes only: Results from the SIOP-WT-2001 Registry. Pediatr. Blood Cancer 2018, 65, e27085. [Google Scholar] [CrossRef] [PubMed]
- Janssens, G.O.; Melchior, P.; Mul, J.; Saunders, D.; Bolle, S.; Cameron, A.L.; Claude, L.; Gurtner, K.; van de Ven, K.P.; van Grotel, M.; et al. The SIOP-Renal Tumour Study Group consensus statement on flank target volume delineation for highly conformal radiotherapy. Lancet Child Adolesc. Health 2020, 4, 846–852. [Google Scholar] [CrossRef]
- Ritchey, M.L.; Green, D.M.; Thomas, P.R.; Smith, G.R.; Haase, G.; Shochat, S.; Moksness, J.; Breslow, N.E. Renal failure in Wilms’ tumor patients: A report from the National Wilms’ Tumor Study Group. Med. Pediatr. Oncol. 1996, 26, 75–80. [Google Scholar] [CrossRef]
- Lange, J.; Peterson, S.M.; Takashima, J.R.; Grigoriev, Y.; Ritchey, M.L.; Shamberger, R.C.; Beckwith, J.B.; Perlman, E.; Green, D.M.; Breslow, N.E. Risk factors for end stage renal disease in non-WT1-syndromic Wilms tumor. J. Urol. 2011, 186, 378–386. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Godzinski, J.; van Tinteren, H.; de Kraker, J.; Graf, N.; Bergeron, C.; Heij, H.; von Schweinitz, D.; Fuchs, J.; Cecchetto, G.; Audry, G.; et al. Nephroblastoma: Does the decrease in tumor volume under preoperative chemotherapy predict the lymph nodes status at surgery? Pediatr. Blood Cancer 2011, 57, 1266–1269. [Google Scholar] [CrossRef]
- Wilde, J.C.; Aronson, D.C.; Sznajder, B.; Van Tinteren, H.; Powis, M.; Okoye, B.; Cecchetto, G.; Audry, G.; Fuchs, J.; Schweinitz, D.V.; et al. Nephron sparing surgery (NSS) for unilateral wilms tumor (UWT): The SIOP 2001 experience. Pediatr. Blood Cancer 2014, 61, 2175–2179. [Google Scholar] [CrossRef]
- Bouty, A.; Blanc, T.; Leclair, M.D.; Lavrand, F.; Faure, A.; Binet, A.; Rod, J.; O’Brien, M.; Sarnacki, S.; Nightingale, M.; et al. Minimally invasive surgery for unilateral Wilms tumors: Multicenter retrospective analysis of 50 transperitoneal laparoscopic total nephrectomies. Pediatr. Blood Cancer 2020, 67, e28212. [Google Scholar] [CrossRef] [PubMed]
- Warmann, S.W.; Godzinski, J.; van Tinteren, H.; Heij, H.; Powis, M.; Sandstedt, B.; Graf, N.; Fuchs, J. Minimally invasive nephrectomy for Wilms tumors in children—Data from SIOP 2001. J. Pediatr. Surg. 2014, 49, 1544–1548. [Google Scholar] [CrossRef]
- Gatta, G.; Botta, L.; Comber, H.; Dimitrova, N.; Leinonen, M.K.; Pritchard-Jones, K.; Siesling, S.; Trama, A.; Van Eycken, L.; van der Zwan, J.M.; et al. The European study on centralisation of childhood cancer treatment. Eur. J. Cancer 2019, 115, 120–127. [Google Scholar] [CrossRef]
- Knops, R.R.G.; van Dalen, E.C.; Mulder, R.L.; Leclercq, E.; Knijnenburg, S.L.; Kaspers, G.J.L.; Pieters, R.; Caron, H.N.; Kremer, L.C.M. The volume effect in paediatric oncology: A systematic review. Ann. Oncol. 2013, 24, 1749–1753. [Google Scholar] [CrossRef]
- Szychot, E.; Apps, J.; Pritchard-Jones, K. Wilms’ tumor: Biology, diagnosis and treatment. Transl. Pediatr. 2014, 3, 12–24. [Google Scholar] [CrossRef]
- Gutierrez, J.C.; Cheung, M.C.; Zhuge, Y.; Koniaris, L.G.; Sola, J.E. Does Children’s Oncology Group hospital membership improve survival for patients with neuroblastoma or Wilms tumor? Pediatr. Blood Cancer 2010, 55, 621–628. [Google Scholar] [CrossRef]
- Fuchs, J.; Kienecker, K.; Furtwängler, R.; Warmann, S.W.; Bürger, D.; Thürhoff, J.W.; Hager, J.; Graf, N. Surgical aspects in the treatment of patients with unilateral wilms tumor: A report from the SIOP 93-01/German Society of Pediatric Oncology and Hematology. Ann. Surg. 2009, 249, 666–671. [Google Scholar] [CrossRef]
- Pastore, G.; Znaor, A.; Spreafico, F.; Graf, N.; Pritchard-Jones, K.; Steliarova-Foucher, E. Malignant renal tumours incidence and survival in European children (1978–1997): Report from the Automated Childhood Cancer Information System project. Eur. J. Cancer 2006, 42, 2103–2114. [Google Scholar] [CrossRef]
- Paintsil, V.; David, H.; Kambugu, J.; Renner, L.; Kouya, F.; Eden, T.; Hesseling, P.; Molyneux, E.; Israels, T. The Collaborative Wilms Tumour Africa Project; baseline evaluation of Wilms tumour treatment and outcome in eight institutes in sub-Saharan Africa. Eur. J. Cancer 2015, 51, 84–91. [Google Scholar] [CrossRef]
- Moreira, C.; Nachef, M.N.; Ziamati, S.; Ladjaj, Y.; Barsaoui, S.; Mallon, B.; Tournade, M.-F. Treatment of nephroblastoma in Africa: Results of the first French African pediatric oncology group (GFAOP) study. Pediatr. Blood Cancer 2012, 58, 37–42. [Google Scholar] [CrossRef]
- Yao, A.J.; Moreira, C.; Traoré, F.; Kaboret, S.; Pondy, A.; Rakotomahefa Narison, M.L.; Guedenon, K.M.; Mallon, B.; Patte, C. Treatment of Wilms Tumor in Sub-Saharan Africa: Results of the Second French African Pediatric Oncology Group Study. J. Glob. Oncol. 2019, 5, 1–8. [Google Scholar] [CrossRef]
- Chagaluka, G.; Paintsil, V.; Renner, L.; Weijers, J.; Chitsike, I.; Borgstein, E.; Kamiza, S.; Afungchwi, G.M.; Kouya, F.; Hesseling, P.; et al. Improvement of overall survival in the Collaborative Wilms Tumour Africa Project. Pediatr. Blood Cancer 2020, 67, e28383. [Google Scholar] [CrossRef]
- Mostert, S.; Arora, R.S.; Arreola, M.; Bagai, P.; Friedrich, P.; Gupta, S.; Kaur, G.; Koodiyedath, B.; Kulkarni, K.; Lam, C.G.; et al. Abandonment of treatment for childhood cancer: Position statement of a SIOP PODC Working Group. Lancet Oncol. 2011, 12, 719–720. [Google Scholar] [CrossRef]
COG | SIOP |
---|---|
Tumor stage | Tumor stage (before and after pre-operative chemotherapy) |
Tumor histology | Tumor histology |
Tumor weight after upfront nephrectomy | Tumor volume after pre-operative chemotherapy |
Patient age | Lung nodule response (stage IV) |
Lung nodule response (stage IV) | |
LOH of chromosome arm 1p and 16q | |
Gain of chromosome arm 1q 1 | |
LOH of chromosome arm 11p15 (in VLRWT only) 1 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Groenendijk, A.; Spreafico, F.; de Krijger, R.R.; Drost, J.; Brok, J.; Perotti, D.; van Tinteren, H.; Venkatramani, R.; Godziński, J.; Rübe, C.; et al. Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature. Cancers 2021, 13, 3142. https://doi.org/10.3390/cancers13133142
Groenendijk A, Spreafico F, de Krijger RR, Drost J, Brok J, Perotti D, van Tinteren H, Venkatramani R, Godziński J, Rübe C, et al. Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature. Cancers. 2021; 13(13):3142. https://doi.org/10.3390/cancers13133142
Chicago/Turabian StyleGroenendijk, Alissa, Filippo Spreafico, Ronald R. de Krijger, Jarno Drost, Jesper Brok, Daniela Perotti, Harm van Tinteren, Rajkumar Venkatramani, Jan Godziński, Christian Rübe, and et al. 2021. "Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature" Cancers 13, no. 13: 3142. https://doi.org/10.3390/cancers13133142